FOLH1 and cancer: RLT has a complex interplay with the tumour microenvironment, with a recent review by Eapen et al. suggesting that beyond PSMA+-cell death, [177Lu]Lu-PSMA-617 treatment may stimulate a systemic immune response which may be harnessed to produce long-lasting cancer immunity [17].